Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Kumar, Ajit
and
Strech, Daniel
2005.
Zuclopenthixol dihydrochloride for schizophrenia.
Cochrane Database of Systematic Reviews,
Velligan, D. I.
Lam, Y.-W. F.
Glahn, D. C.
Barrett, J. A.
Maples, N. J.
Ereshefsky, L.
and
Miller, A. L.
2005.
Defining and Assessing Adherence to Oral Antipsychotics: A Review of the Literature.
Schizophrenia Bulletin,
Vol. 32,
Issue. 4,
p.
724.
2007.
Therapie der Schizophrenie.
p.
167.
Lincoln, Tania Marie
and
Hodgins, Sheilagh
2008.
Is Lack of Insight Associated With Physically Aggressive Behavior Among People With Schizophrenia Living in the Community?.
Journal of Nervous & Mental Disease,
Vol. 196,
Issue. 1,
p.
62.
Witzel, Joachim G.
Gubka, Udo
Weisser, Heike
and
Bogerts, Bernhard
2008.
Antipsychotic polypharmacy in the emergency treatment of highly aggressive schizophrenic prisoners ‐ a retrospective study.
International Journal of Prisoner Health,
Vol. 4,
Issue. 2,
p.
96.
Castberg, Ingrid
and
Spigset, Olav
2008.
Prescribing Patterns and the Use of Therapeutic Drug Monitoring of Psychotropic Medication in a Psychiatric High-Security Unit.
Therapeutic Drug Monitoring,
Vol. 30,
Issue. 5,
p.
597.
Fernández Sánchez, Anna
Pinto-Meza, Alejandra
and
Maria Haro, Josep
2009.
Comparing the efficacy of long-acting pharmaceutical forms (depot) versus oral forms of the atypical and conventional antipsychotics marketed in Spain for treating patients with schizophrenia.
Revista de Psiquiatría y Salud Mental (English Edition),
Vol. 2,
Issue. 1,
p.
5.
Mauri, Massimo Carlo
Turner, Martin
Volonteri, Lucia S.
Medori, Rossella
and
Maier, Wolfgang
2009.
Dosing patterns in Europe: Efficacy and safety of risperidone long-acting injectable in doses of 25, 37.5 and 50 mg.
International Journal of Psychiatry in Clinical Practice,
Vol. 13,
Issue. 1,
p.
36.
Fernández Sánchez, Anna
Pinto-Meza, Alejandra
and
Maria Haro, Josep
2009.
Comparación de la eficacia de las formas farmacéuticas de liberación retardada (depot) y las orales de los antipsicóticos típicos y atípicos comercializados en España para pacientes diagnosticados de esquizofrenia.
Revista de Psiquiatría y Salud Mental,
Vol. 2,
Issue. 1,
p.
5.
Vandamme, M.-J.
2009.
Schizophrénie et violence : facteurs cliniques, infracliniques et sociaux.
Annales Médico-psychologiques, revue psychiatrique,
Vol. 167,
Issue. 8,
p.
629.
Anckarsäter, Henrik
Radovic, Susanna
Svennerlind, Christer
Höglund, Pontus
and
Radovic, Filip
2009.
Mental disorder is a cause of crime: The cornerstone of forensic psychiatry.
International Journal of Law and Psychiatry,
Vol. 32,
Issue. 6,
p.
342.
Haddad, Peter M.
Taylor, Mark
and
Niaz, Omair S.
2009.
First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: Systematic review of randomised controlled trials and observational studies.
British Journal of Psychiatry,
Vol. 195,
Issue. S52,
p.
s20.
Bobes, J.
Fillat, O.
and
Arango, C.
2009.
Violence among schizophrenia out‐patients compliant with medication: prevalence and associated factors.
Acta Psychiatrica Scandinavica,
Vol. 119,
Issue. 3,
p.
218.
David, Anthony S.
Gibbs, Ayana
and
Patel, Maxine X.
2010.
Advances in Schizophrenia Research 2009.
p.
403.
Furiak, Nicolas M.
Ascher-Svanum, Haya
Klein, Robert W.
Smolen, Lee J.
Lawson, Anthony H.
Montgomery, William
and
Conley, Robert R.
2011.
Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model.
Current Medical Research and Opinion,
Vol. 27,
Issue. 4,
p.
713.
Voyer, M.
Jaafari, N.
and
Senon, J.-L.
2011.
Insight et comportements violents chez les patients souffrant d’une schizophrénie.
Annales Médico-psychologiques, revue psychiatrique,
Vol. 169,
Issue. 7,
p.
441.
Leucht, Claudia
Heres, Stephan
Kane, John M.
Kissling, Werner
Davis, John M.
and
Leucht, Stefan
2011.
Oral versus depot antipsychotic drugs for schizophrenia—A critical systematic review and meta-analysis of randomised long-term trials.
Schizophrenia Research,
Vol. 127,
Issue. 1-3,
p.
83.
Gearing, Robin E.
Townsend, Lisa
MacKenzie, Michael
and
Charach, Alice
2011.
Reconceptualizing Medication Adherence: Six Phases of Dynamic Adherence.
Harvard Review of Psychiatry,
Vol. 19,
Issue. 4,
p.
177.
Barnes, Thomas RE
2011.
Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology.
Journal of Psychopharmacology,
Vol. 25,
Issue. 5,
p.
567.
Scheifes, A.
Stolker, J. J.
Egberts, A. C. G.
Nijman, H. L. I.
and
Heerdink, E. R.
2011.
Representation of people with intellectual disabilities in randomised controlled trials on antipsychotic treatment for behavioural problems.
Journal of Intellectual Disability Research,
Vol. 55,
Issue. 7,
p.
650.
Comments
No Comments have been published for this article.